Abstract: A tablet formed from a pre-lyophilization solution has a void in its bottom surface, with a void height that is about 60% to 100% of a depth of the tablet. A pharmaceutical dosage form includes a blister sheet having one or more cavities, each having a protrusion extending upwardly from the cavity floor, with a tablet formed in the cavity by lyophilization of a pre-lyophilization solution in each such cavity. The protrusion is a cylinder or tapered cylinder and the void has a corresponding shape. A film overlays the blister sheet to seal the tablet in the blister sheet cavities.

Abstract: A lyophilization promoting element to facilitate the transfer of heat between a lyophilizer and a pre-lyophilization solution. The element includes a base plate with a plurality of apertures. The base plate is made of a thermally conductive material and the apertures are regularly arranged within the base plate, each aperture being sized to receive a pharmaceutical vial container containing a pre-lyophilization solution. A method of lyophilizing includes inserting one or more pharmaceutical vial containers into the plurality of apertures of the lyophilization promoting element and placing the lyophilization promoting element holding the one or more pharmaceutical vial containers on a shelf of a lyophilizer.

Abstract: Solid compositions having about 150 mg to about 245 mg Fosaprepitant that are stable after storage at about 25° C. for 6 months and processes for preparing solid Fosaprepitant compositions that are stable after long term storage at room temperature. The processes include freezing a Fosaprepitant solution in the primary packaging container at a first freezing temperature; applying vacuum at second temperature that is higher than the freezing temperature; fully stoppering the primary packaging container; and sealing the stoppered primary packaging container.

Abstract: A multiple dose Naloxone spray dosage form provides a container having two or more unit doses of Naloxone or a salt thereof in a liquid that is delivered by a metered dosage spray pump. In different embodiments, ten or more, 3-500, and 10-500 unit doses are provided in the container. The metered dosage spray pump delivers 50 to about 200 ?L of Naloxone solution per spray, preferably, 100 ?L per spray. Each unit dose contains about 0.5 mg to 12 mg of Naloxone or a pharmaceutically acceptable salt thereof, preferably, about 2 mg to 4 mg thereof in the delivered spray. A stable pharmaceutically acceptable composition of Naloxone is used in the multiple dose Naloxone spray dosage form. A method of treatment of opioid overdose involves administration of multiple doses using the multiple dose Naloxone spray dosage form.

Abstract: A lyophilization promoting element to facilitate the transfer of heat between a lyophilizer and a pre-lyophilization solution. The element includes a base plate with a plurality of apertures. The base plate is made of a thermally conductive material and the apertures are regularly arranged within the base plate, each aperture being sized to receive a pharmaceutical vial container containing a pre-lyophilization solution. A method of lyophilizing includes inserting one or more pharmaceutical vial containers into the plurality of apertures of the lyophilization promoting element and placing the lyophilization promoting element holding the one or more pharmaceutical vial containers on a shelf of a lyophilizer.

Abstract: A pharmaceutically acceptable formulation of cannabinoid for non-oral delivery. The formulation including at least one cannabinoid at 0.05% to 50% by weight of the total formulation. The formulation being delivered to a patient to alleviate symptoms including, but not limited to, pain, nausea, vomiting, and the like.

Abstract: Solid compositions having about 150 mg to about 245 mg Fosaprepitant that are stable after storage at about 25° C. for 6 months and processes for preparing solid Fosaprepitant compositions that are stable after long term storage at room temperature. The processes include freezing a Fosaprepitant solution in the primary packaging container at a first freezing temperature; applying vacuum at second temperature that is higher than the freezing temperature; fully stoppering the primary packaging container; and sealing the stoppered primary packaging container.

Abstract: Sterile pharmaceutical products of Fosaprepitant and a 5-HT3 blocker for parenteral administration including a container containing a formulation of Fosaprepitant or a pharmaceutically acceptable salt thereof and 5-HT3 blocker. The formulations may comprise surface-active agent and a pharmaceutically acceptable vehicle. The formulations may be lyophilized and diluted prior to administration or ready to use liquids or a pre-lyophilization solution.

Abstract: Stable ready to use pharmaceutical compositions of Ribavirin including a primary packaging container containing a sterile aqueous Ribavirin solution having a concentration of 10 mg/mL to 40 mg/mL Ribavirin and a seal sealing the primary packaging container. The Ribavirin solution is free of viable microbial contamination in in accordance with the test methods in 40 USP <71> using Trypticase Soy Broth and Fluid Thioglycollate Medium. A method of manufacturing ready to use Ribavirin solutions by terminally sterilizing a Ribavirin solution. Methods of treating respiratory syncytial virus by administering ready to use 20 mg/mL Ribavirin solutions in a nebulizer.